August 12, 2025 – OptoSeeker Biotech (Shenzhen) Co., Ltd. (hereinafter referred to as OptoSeeker Biotech) and MGI have announced a strategic partnership. This collaboration will leverage both parties' technological and platform strengths in the life sciences to jointly create an antibody discovery platform covering the entire workflow of "screening-sequencing-data analysis," accelerating the industrialization of life science instruments.
Building an Antibody Discovery Platform Together
OptoSeeker Biotech is an innovative life sciences company dedicated to transforming new drug discovery. It develops cutting-edge life science instruments to accelerate biological research and development. Its proprietary single-cell functional screening platform can accurately identify and isolate the "seed" B cells with the greatest therapeutic potential from tens of thousands of cells.
As a provider of core tools for life sciences, MGI focuses on the R&D of underlying technologies and product innovation for core tools centered around the central dogma of "reading, writing, and storing" life. It continuously provides users with system solutions covering all scenarios and the entire life cycle of life science research and applications. MGI has not only achieved a comprehensive strategic layout of gene sequencing products across three technological paths—"excited light," "spontaneous light," and "non-light"—but is also the world's first company to possess both massively commercial-scale short-read and long-read sequencing products.
Focusing on the cutting-edge needs of the domestic market, the two parties will work closely to further break through the core bottlenecks in antibody drug R&D, significantly shortening the antibody discovery cycle and providing an innovative driving force to tackle major diseases affecting national health.
Dr. Hainan Xie, CEO of OptoSeeker Biotech (left), and Jian Liu, Executive Vice President of MGI (right), represent their respective companies at the signing of the strategic partnership agreement.
Dr. Hainan Xie, CEO of OptoSeeker Biotech, stated: "We are very proud to join hands with MGI, the leading sequencing company in China. This strategic partnership is not only a business-level partnership but also a powerful testament to the synergistic development of China's local innovation capabilities, perfectly aligning with the national strategy of building a strong and independent health industry. This collaboration fully demonstrates our determination and strength in creating world-class technology locally in China."
Jian Liu, Executive Vice President of MGI, said: "As the 'creator of core tools for life sciences,' MGI is committed to providing advanced equipment platforms and an open ecosystem for global users. We look forward to working with OptoSeeker Biotech to jointly explore a new ecosystem for drug discovery that is based locally and benefits the world."
A Tripartite Effort to Build a Closed-Loop, AI-Driven Innovative Drug R&D System
Notably, the collaboration between OptoSeeker Biotech and MGI will be further integrated with the AI-powered pharmaceutical company BioMap. Using the foundational life science large model built by BioMap, a deep analysis will be performed on the massive single-cell functional data and corresponding sequencing fusion data generated from OptoSeeker's OptoBot® series platform. This will enable the prediction, design, and optimization of more clinically promising antibody drugs, forming a next-generation drug R&D closed-loop system of "Screening—Sequencing—AI-driven Intelligence" led by Chinese enterprises.
The OptoBot® series of products, including the OptoBot® 500 Optoelectronic Microfluidic System and the coming soon OptoBot® Series Single-Cell Optofluidic System.
The full-chain platform jointly built by OptoSeeker Biotech, MGI, and BioMap demonstrates a comprehensive breakthrough in drug discovery capabilities, from key technologies to system integration. It will help advance the domestic drug R&D system into a new stage of development that is fully autonomous and intelligently driven.
Group photo at the OptoSeeker Biotech Shenzhen office
About OptoSeeker Biotech
Optoseeker Biotech is dedicated to developing cutting-edge life science instruments to accelerate biological research and development. The company has successfully built the OptoBot® series of products with its own independent intellectual property rights, deeply integrating core technologies such as optoelectronic tweezers (OET), microfluidics, biochips, fluorescent staining, and protein labeling. Its core advantage lies in the ability to achieve full-process automation from single-cell importation, culture, characterization, and sorting to exportation, significantly improving experimental efficiency and reproducibility. It provides researchers with powerful tools for high-throughput single-cell analysis and manipulation, continuously driving innovation in the biomedical field.
Currently, our core products include optofluidic systems, digital microfluidic systems, structured light projectors, and more. Our applications cover multiple fields, including antibody drug development, cell line development, cell and gene therapy (CGT), and micro-nano manipulation, providing a solid guarantee for our customers' research and production activities.
About MGI
Shenzhen MGI Tech Co., Ltd. (MGI) adheres to the concept of "Innovation, Intelligence, Leading Life Sciences." It focuses on the R&D of underlying technologies and product innovation for core tools centered around the central dogma of "reading, writing, and storing" life. It continuously provides users with system solutions covering all scenarios and the entire life cycle of life science research and applications. MGI is committed to advancing scientific breakthroughs and clinical application transformation through multi-omics technologies centered on gene sequencing, and to building an open, cooperative, and win-win industry ecosystem with upstream and downstream partners in the life sciences and biotechnology industries.
Established in 2016, MGI's business spans over 110 countries and regions across six continents as of December 31, 2024. It has established 9 R&D centers, 7 production bases, 9 international warehouses, and 13 customer experience centers worldwide, serving a cumulative total of over 3,300 users. As a provider of core tools for life sciences, MGI has not only achieved a comprehensive strategic layout of gene sequencing products across three technological paths—"excited light," "spontaneous light," and "non-light"—but is also the world's first company to possess both massively commercial-scale short-read and long-read sequencing products.
About BioMap
BioMap is a global pioneer in foundational models for life sciences. Our 210-billion-parameter biological language model decodes the fundamental principles of genomes, proteins, cells, and biological systems. Functioning as a high-fidelity biological simulator, it significantly reduces reliance on traditional experimental models, accelerating and empowering R&D.
To date, BioMap has achieved state-of-the-art (SOTA) results across 200+ tasks spanning drug discovery, biomanufacturing, fundamental research, and healthcare. We deliver model-driven professional AI agents to 700+ global clients in dozens of specialized domains. By integrating data, modeling, and experimental capabilities, we enable cutting-edge outcomes including accelerated drug discovery, boosted bio-reaction efficiency, advanced biological data interpretation, and streamlined knowledge acquisition.
